Imagine a smartwatch that doesn't just track your steps, but actually 'sees' the chemistry of your blood through your skin. It uses a tiny, high-tech light beam to detect warning signs of heart disease and diabetes without needing a single needle. It's like having a professional medical lab shrunk down to fit on your wrist.
Healthcare is currently reactive, meaning patients only seek help after symptoms appear. This is critical for metabolic syndrome, which leads to heart attacks and strokes but is often undetected until it is too late.
A miniature Mid-Infrared spectrometer including QCL chips, sensors, and wavelength-selecting filters capable of non-invasive biomarker detection.
If you are a wearable manufacturer dealing with the limitation of only tracking heart rate or steps — this project developed a miniature Mid-Infrared spectrometer that monitors biomarkers for metabolic syndrome non-invasively. This allows for lab-level precision in a consumer device.
If you are a digital health provider dealing with reactive patient care for obesity and diabetes — this project developed a real-time monitoring tool that detects ketones and uric acid. This enables a shift toward proactive healthcare and personalized medicine.
If you are a clinic dealing with the high cost and waste of frequent blood draws for chronic patients — this project developed a pain-free skin sensor. This reduces the need for invasive sampling while maintaining diagnostic accuracy.
Based on available project data, the specific unit price is not mentioned, but the project aims to reduce the high cost typically associated with laboratory-grade MIR spectrometers.
The project has successfully designed and fabricated QCL chips and sensors that meet size and power constraints for a PoC demonstrator, suggesting a path toward industrial scaling.
Based on available project data, specific licensing terms are not provided, but the project is coordinated by Quantune Technologies GmbH with a consortium of 6 partners.
The project utilizes Artificial Intelligence and Generative AI to analyze biomarkers, implying integration with digital health data pipelines.
The project period is from 2024-01-01 to 2027-06-30, indicating the development phase is ongoing until mid-2027.
The consortium is highly balanced for commercialization, featuring a 50% industry ratio with 3 SMEs and 3 other partners across 6 countries. Led by an SME (Quantune Technologies GmbH), the group blends deep technical expertise in laser physics and AI with biomedical research and business management, reducing the gap between lab research and market entry.
Contact Quantune Technologies GmbH in Germany
Contact us to explore licensing opportunities for MIR wearable sensors.
